

PHARMACEUTICAL 2023

POINT Biopharma Global Inc. Rank 20 of 446







RealRate

PHARMACEUTICAL 2023

POINT Biopharma Global Inc. Rank 20 of 446

The relative strengths and weaknesses of POINT Biopharma Global Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of POINT Biopharma Global Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 99% points. The greatest weakness of POINT Biopharma Global Inc. is the variable Other Assets, reducing the Economic Capital Ratio by 3.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 279%, being 236% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	530,823
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	79,738
Liabilities, Non-Current	10,178
Other Assets	16,119
Other Compr. Net Income	-457
Other Expenses	31,293
Other Liabilities	1,452
Other Net Income	4,064
Other Revenues	226,580
Property and Equipment	31,381
Research and Development	82,050
Selling, General and Administrative Expense	19,007

Output Variable	Value in 1000 USD
Assets	578,323
Liabilities	91,369
Expenses	132,350
Revenues	226,580
Stockholders Equity	486,954
Net Income	98,293
Comprehensive Net Income	98,065
Economic Capital Ratio	279%

